| Literature DB >> 33613277 |
Li Li1, Weixing Dai2, Wenting Li1, Yumao Zhang1, Yanqin Wu1, Chenfeng Guan1, Anye Zhang3, Hui Huang4, Yuzhen Li1.
Abstract
Myocardial ischemia (MI) is one of the most common cardiovascular diseases with high incidence and mortality. Huang-Lian-Jie-Du-Tang (HLJDT) is a classic traditional Chinese prescription to clear "heat" and "poison". In this study, we used a deliberate strategy integrating the methods of network pharmacology, pharmacodynamics, and metabonomics to investigate the molecular mechanism and potential targets of HLJDT in the treatment of MI. Firstly, by a network pharmacology approach, a global view of the potential compound-target-pathway network based on network pharmacology was constructed to provide a preliminary understanding of bioactive compounds and related targets of HLJDT for elucidating its molecular mechanisms in MI. Subsequently, in vivo efficacy of HLJDT was validated in a rat model. Meanwhile, the corresponding metabonomic profiles were used to explore differentially induced metabolic markers thus providing the metabolic mechanism of HLJDT in treating MI. The results demonstrated the myocardial protection effect of HLJDT on ischemia by a multicomponent-multitarget mode. This study highlights the reliability and effectiveness of a network pharmacology-based approach that identifies and validates the complex of natural compounds in HLJDT for illustrating the mechanism for the treatment of MI.Entities:
Keywords: HLJDT; metabonomics; multitarget; myocardial ischemia; network pharmacology
Year: 2021 PMID: 33613277 PMCID: PMC7890363 DOI: 10.3389/fphar.2020.589175
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810